Merck Profit Margin 2010-2023 | MRK

Current and historical gross margin, operating margin and net profit margin for Merck (MRK) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Merck net profit margin as of December 31, 2023 is 0.61%.
Merck Annual Profit Margins
Merck Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $327.548B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.285B 121.78
Novo Nordisk (NVO) Denmark $558.788B 46.03
Johnson & Johnson (JNJ) United States $386.487B 15.38
AbbVie (ABBV) United States $312.224B 15.91
Novartis AG (NVS) Switzerland $217.895B 15.10
AstraZeneca (AZN) United Kingdom $198.827B 17.62
Pfizer (PFE) United States $155.559B 15.06
Sanofi (SNY) $120.914B 10.89
Innoviva (INVA) United States $0.992B 8.95